Published : 21 Aug 2023

---

Aagami has a new client. This time it is a new subsidiary of an existing client from New York.

 

The new client is focused on understanding the role of autoantibodies and how they may promote both acute and chronic autoimmune disease. Their R&D team are designing a full computational-to-experimental flow to predict and validate antigenic epitopes that may contribute to autoimmune pathologies. 

 

The assignment received by Aagami is to support their strategic initiatives such as fund raising and partnering. 

 

We at Aagami are excited as this is yet another example of a satisfied client putting their trust again in Aagami and awarding more opportunities to support them and their network.